



# HOKKAIDO UNIVERSITY

Title	Fibrinogen level deteriorates before other routine coagulation parameters and massive transfusion in the early phase of severe trauma : a retrospective observational study
Author(s)	Hayakawa, Mineji; Gando, Satoshi; Ono, Yuichi et al.
Citation	Seminars in thrombosis and hemostasis, 41(01), 35-42 <a href="https://doi.org/10.1055/s-0034-1398379">https://doi.org/10.1055/s-0034-1398379</a>
Issue Date	2015-02
Doc URL	<a href="https://hdl.handle.net/2115/60618">https://hdl.handle.net/2115/60618</a>
Type	journal article
File Information	Reftext07013.pdf



**Fibrinogen level deteriorates before other routine coagulation parameters and massive transfusion in the early phase of severe trauma: A retrospective observational study**

Mineji Hayakawa, MD, PhD; Satoshi Gando, MD, PhD; Yuichi Ono, MD; Takeshi Wada, MD; Yuichiro Yanagida, MD; Atsushi Sawamura, MD, PhD

Emergency and Critical Care Center, Hokkaido University Hospital, N14W5,  
Kita-ku, Sapporo 060-8648 Japan

**Corresponding author**

Mineji Hayakawa, MD, PhD

Emergency and Critical Care Center, Hokkaido University Hospital,  
N14W5, Kita-ku, Sapporo 060-8648, Japan

TEL: +81-11-706-7377/FAX: +81-11-706-7378/E-mail: [mineji@dream.com](mailto:mineji@dream.com)

## **Abstract**

**Introduction:** In trauma, hemostatic functions should be maintained appropriately to prevent massive bleeding. This study elucidated the time-dependent changes in platelet count and coagulation variables, and the effects of disseminated intravascular coagulation (DIC) on these changes during the early phase of trauma.

**Methods:** Trauma patients with an injury severity score  $\geq 16$  were enrolled. The critical levels of platelet count and coagulation variables were defined according to recent trauma guidelines. Massive transfusion was defined as  $>10$  units red cell concentrate. The time from arrival at the emergency department to reaching the critical levels and meeting the criteria for massive transfusion were evaluated.

**Results:** Eighty trauma patients were enrolled; 35 were diagnosed with DIC on arrival. Among all patients, fibrinogen levels reached the critical level earliest among routine coagulation parameters; other routine coagulation parameters deteriorated after the patients met the criteria for massive transfusion. Routine coagulation parameters reached their critical levels earlier in DIC patients than patients without DIC. Massive transfusion was performed more frequently in

DIC patients, who met the criteria earlier.

**Conclusions:** During the early phase of trauma, fibrinogen levels deteriorate earlier than other routine coagulation parameters, especially in DIC patients.

**Keywords**

Disseminated intravascular coagulation, fibrinolysis, fibrinogenolysis, coagulopathy, hemorrhage

## Introduction

Trauma-induced coagulopathy (TIC) is a multifactorial condition including hemodilution, hypothermia, and traumatic coagulopathy caused by trauma and traumatic shock<sup>1-3</sup>. We previously reported disseminated intravascular coagulation (DIC) with the fibrinolytic phenotype is the predominant mechanism of TIC<sup>1-3</sup>. We also reported DIC on arrival at the emergency department can predict massive transfusion and poor outcomes in patients with severe trauma<sup>4-6</sup>. Furthermore, we found DIC during the early phase of trauma is characterized by hyper-fibrin(ogen)olysis<sup>4-6</sup>. In DIC with the fibrinolytic phenotype, the consumption of platelets and coagulation factors, and hyper-fibrin(ogen)olysis induces bleeding tendency<sup>4-6</sup>.

Fibrinogen plays an important role in clot formation and is substantially diminished as a result of hyper-fibrin(ogen)olysis. Therefore, low fibrinogen levels are associated with hemostatic impairment and induce massive bleeding<sup>7,8</sup>.

Several studies indicate low fibrinogen level is a strong risk factor for poor outcomes in trauma patients<sup>9-14</sup>. Schochl et al. evaluated fibrinogen levels by whole-blood thromboelastometry upon arrival at the emergency department and report fibrinogen level predicts massive transfusion in trauma patients<sup>9</sup>.

Meanwhile, Chambers et al. report low fibrinogen level is almost always the initial abnormality prompting the implementation of massive transfusion protocols <sup>10</sup>.

Previous studies indicate fibrinogen deficiency develops before other hemostatic abnormalities in both major surgery patients <sup>15,16</sup> and animal models <sup>17,18</sup>. Hiippala et al. <sup>15,16</sup> report fibrinogen levels reach 1.0 g/L at 142% blood loss and that hemodilution and fibrinogen deficiency develop before other hemostatic abnormalities in major surgery patients; they carefully monitored blood loss and immediately performed transfusions to ensure stable blood volume <sup>15</sup>. However, massive bleeding in severe trauma patients is very different from the conditions in their study <sup>15,16</sup>. Furthermore, the pathogenesis of TIC differs from that of the coagulation abnormality induced by massive blood loss in major surgery <sup>1-3</sup>. Severe trauma is often accompanied by DIC with the fibrinolytic phenotype due to massive tissue injuries and prolonged hypoperfusion.

Several guidelines indicate fibrinogen levels should be kept  $\geq 1.5$  g/L to maintain hemostatic functions <sup>7,19-22</sup>. The updated European trauma guidelines recommend maintaining fibrinogen levels  $\geq 1.5-2.0$  g/L <sup>19,23</sup>, which was increased from 1.0 g/L in previous guidelines <sup>24-27</sup>. Meanwhile, in our previous report, the optimal cut-off of fibrinogen for the prediction of death and massive transfusion

was 1.9 g/L<sup>5</sup>. Recent studies highlight the importance of fibrinogen supplementation in trauma patients<sup>28-33</sup>. Stinger et al. indicate transfusion with a greater fibrinogen/red cell concentrate ratio is associated with better survival of severe trauma patients with massive transfusion<sup>28</sup>.

Accordingly, the present study elucidated the time-dependent changes in platelet count and coagulation variables including fibrinogen levels during the early phase of severe trauma. This study also investigated the influences of DIC upon arrival at the emergency department on the time-dependent changes in platelet count and coagulation variables.

## **Materials and Methods**

The present retrospective observational study was approved by the Institutional Review Board of Hokkaido University Hospital; the need for informed consent was waived, because this was a retrospective observational study.

### *Patient Selection and Data Collection*

From January 2010 to December 2012, all trauma patients with an injury

severity score  $\geq 16$ <sup>34</sup> admitted to the emergency department were retrospectively evaluated. Patients were excluded if they were younger than 16 years or complicated with cardiac arrest, burn, or cervical spine injury caused by a minor accident. The clinical backgrounds and laboratory test results (i.e., complete blood counts, coagulation, and biochemistry variables) of the patients were collected retrospectively from computer-based patient records. Blood samples were drawn promptly on arrival at the emergency department, and laboratory tests were immediately performed according to routine protocols. Laboratory tests were repeated as necessary. The laboratory test results during the first 24 hours were analyzed.

The patients were divided in 2 groups: those with and without DIC upon arrival at the emergency department. DIC was evaluated according to the scoring algorithm of the Japanese Association for Acute Medicine DIC criteria<sup>35</sup>. Massive transfusion was defined as  $>10$  units of red cell concentrate. We calculated total fibrinogen administration on the basis of the standard amounts of fibrinogen contained in each blood component: 1 unit of fresh frozen plasma (FFP, 120 mL) and platelet concentrate (10 mL) contained 400 and 300 mg fibrinogen, respectively. The critical levels for platelet count and coagulation variables were defined on the basis of the European trauma guideline for the management of

bleeding following major trauma <sup>19,23</sup> as follows: platelet count,  $\leq 50$  or  $\leq 100 \times 10^9/L$  (in patients with brain trauma); prothrombin time-international normalized ratio (PT-INR),  $\geq 1.5$ ; activated partial thromboplastin time (APTT),  $\geq 60$  s; fibrinogen,  $\leq 1.5$  g/L.

### *Statistical Analysis*

All variables are expressed as median and interquartile range (1st to 3rd quartile) or number (percent). Kaplan–Meier analyses were performed to evaluate the time from arrival at the emergency department to reaching the critical levels for platelet count and coagulation variables. Kaplan–Meier analysis was also performed to evaluate the time from arrival at the emergency department to the time when patients met the criteria for massive transfusion. Intergroup comparisons were made using the Mann–Whitney  $U$ -test,  $\chi^2$  test, and the log-rank test in Kaplan–Meier analyses. SPSS 15.0J (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses. The level of significance was set at  $P < 0.05$ .

### **Results**

A total of 80 trauma patients were enrolled, and 35 were diagnosed with DIC on arrival at the emergency department. The characteristics of the patients are shown in Table 1. Among all patients, 85% were transferred to the emergency department within 60 minutes after accidents and 75% did not receive fluid resuscitation before arrival. Patients with DIC had higher injury severity scores than patients without DIC. In addition, injuries to the abdomen and extremities were more severe in patients with DIC than those without DIC. The physiologic status (i.e., Glasgow coma scale, blood pressure, and heart rate) of patients with DIC on arrival was more severe than that of patients without DIC.

The results of laboratory tests on arrival at the emergency department are shown in Table 2. Remarkably elevated fibrin/fibrinogen degradation products (FDP) and D-dimer levels were observed in patients with DIC on arrival. Patients with DIC had poorer laboratory test results than those without DIC. The elevation of the FDP/D-dimer ratio, a marker of fibrinolysis, was higher in patients with DIC than those without DIC. Laboratory tests were repeated a median of 3 (IQR: 2–4) times/patient during the first 24 hours.

Transfusions during the first 6 and 24 hours are shown in Table 3. Patients with DIC received more transfusions and more units of all blood components than patients without DIC. Most patients with DIC received FFP and

fibrinogen concentrate transfusions during the first 6 hours after arrival at the emergency department.

Table 4 shows the treatments and outcomes of the patients. Emergency operations for hemostasis were performed more frequently in patients with DIC than those without DIC. Most other emergency operations were craniotomies. During the first 24 hours, 2 patients died from massive bleeding and primary brain injury. Another 7 patients died from primary brain injury more than 48 hours after hospital admission for a total of 9 in-hospital deaths.

The Kaplan–Meier estimation curves of the time from arrival at the emergency department to reaching the critical levels for platelet count and coagulation variables as well as the time to meeting the criteria for massive transfusion among all patients are shown in Figure 1; the associations between the Kaplan–Meier analyses are shown in Table 5. Fibrinogen levels reached the critical level earliest among the routine coagulation parameters. Furthermore, the other routine coagulation parameters reached their respective critical levels after the patients met the criteria for massive transfusion. Fibrinogen levels decreased below 1.5 g/L during the first 12 hours in 42 patients (53%).

The Kaplan–Meier estimation curves for the time from arrival at the emergency department to reaching the critical levels for platelet count and

coagulation variables as well as the time to meeting the criteria for massive transfusion in patients with and without DIC are presented separately in Figure 2. Platelet count and all coagulation variables except APTT reached their respective critical levels earlier in patients with DIC than those without DIC. The criteria for massive transfusion were met earlier and more frequently in patients with DIC than those without DIC.

## **Discussion**

The present study demonstrates that fibrinogen reaches its critical level before the other routine coagulation parameters in trauma patients. Furthermore, only fibrinogen deterioration was observed before patients met the criteria for massive transfusion. Patients with DIC received more transfusions and units of all blood components than patients without DIC. Furthermore, the routine coagulation parameters deteriorated earlier in patients with DIC than those without DIC. Fibrin(ogen)olysis was more severe in patients with DIC than those without DIC.

In trauma patients, DIC with the fibrinolytic phenotype upon arrival at the emergency department is observed before hemodilution<sup>4-6</sup>. DIC during the

early phase of trauma is characterized by the consumption of platelets and coagulation factors as well as hyper-fibrin(ogen)olysis<sup>4-6</sup>. The present study confirms the consumption of coagulation factors and hyper-fibrin(ogen)olysis on the basis of prolonged PT and APTT, decreased fibrinogen levels, and increased FDP and D-dimer levels. In particular, an increased FDP/D-dimer ratio indicates hyper-fibrinogenolysis. DIC patients already present with a bleeding tendency on arrival at the emergency department.

The active administration of coagulation factors with FFP and fibrinogen concentrate is recommended for damage-control resuscitation in severe trauma patients<sup>1,36</sup>. Fibrinogen supplementation is especially important in severe trauma patients, because fibrinogen plays an important role in clot formation<sup>28-33</sup>. In the present study, patients were administered large quantities of FFP and fibrinogen concentrates during the early phase of trauma. However, we were unable to prevent decreases in fibrinogen levels. We term this phenomenon “DIC-induced consumption coagulopathy.”

Although fibrinogen plays an important role in the resuscitation of severe trauma patients, fibrinogen levels are not measured routinely in the emergency departments of many trauma centers<sup>8,37</sup>; in an international survey of clinical practice, Hoyt et al. report that fibrinogen levels are measured routinely when

trauma patients arrive at the emergency department in only 36% of trauma centers<sup>37</sup>. For 30 years, we have been routinely measuring fibrinogen levels along with other routine coagulation parameters when trauma patients arrive at the emergency department. In the present study, fibrinogen levels were measured along with other routine coagulation parameters a median of 3 (IQR: 2–4) times/patient during the first 24 hours after arrival at the emergency department. Routine coagulation parameters, especially fibrinogen level, should be repeatedly measured in severe trauma patients during the first several hours after arrival at the emergency department.

## **Conclusions**

During the early phase of trauma, fibrinogen levels deteriorate earlier and more frequently than other routine coagulation parameters (i.e., PT, APTT, and platelet count), especially in patients with DIC. Only the deterioration of fibrinogen levels precedes patients meeting the criteria for massive transfusion.

## **Competing interests**

The authors declare that they have no competing interests.

### **Authors' contributions**

MH: study design, data acquisition and interpretation, statistical analysis, and drafting of the manuscript; SG: data interpretation and drafting of the manuscript; YO, TW, YY, AS: data interpretation. All authors have read and approved the final manuscript.

## References

- 1) Gando S, Sawamura A, Hayakawa M: Trauma, shock, and disseminated intravascular coagulation: lessons from the classical literature. *Ann Surg* 2011; 254: 10-9.
- 2) Gando S: Acute coagulopathy of trauma shock and coagulopathy of trauma: a rebuttal. You are now going down the wrong path. *J Trauma* 2009; 67: 381-3.
- 3) Gando S: Disseminated intravascular coagulation in trauma patients. *Semin Thromb Hemost* 2001; 27: 585-92.
- 4) Hayakawa M, Sawamura A, Gando S, Kubota N, Uegaki S, Shimojima H, Sugano M, Ieko M: Disseminated intravascular coagulation at an early phase of trauma is associated with consumption coagulopathy and excessive fibrinolysis both by plasmin and neutrophil elastase. *Surgery* 2011; 149: 221-30.
- 5) Sawamura A, Hayakawa M, Gando S, Kubota N, Sugano M, Wada T, Katabami KI: Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality. *Thromb Res* 2009; 124: 608-13.

- 6) Gando S, Kameue T, Matsuda N, Hayakawa M, Ishitani T, Morimoto Y, Kemmotsu O: Combined activation of coagulation and inflammation has an important role in multiple organ dysfunction and poor outcome after severe trauma. *Thromb Haemost* 2002; 88: 943-9.
- 7) Levy JH, Szlam F, Tanaka KA, Sniecinski RM: Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. *Anesth Analg* 2012; 114: 261-74.
- 8) Schlimp CJ, Schochl H: The role of fibrinogen in trauma-induced coagulopathy. *Hamostaseologie* 2013; 34: 29-39.
- 9) Schochl H, Cotton B, Inaba K, Nienaber U, Fischer H, Voelckel W, Solomon C: FIBTEM provides early prediction of massive transfusion in trauma. *Crit Care* 2011; 15: R265.
- 10) Chambers LA, Chow SJ, Shaffer LE: Frequency and characteristics of coagulopathy in trauma patients treated with a low- or high-plasma-content massive transfusion protocol. *Am J Clin Pathol* 2011; 136: 364-70.
- 11) Inaba K, Karamanos E, Lustenberger T, Schochl H, Shulman I, Nelson J, Rhee P, Talving P, Lam L, Demetriades D: Impact of fibrinogen levels on outcomes after acute injury in patients requiring a massive transfusion. *J Am Coll Surg* 2013; 216: 290-7.

- 12) Schochl H, Solomon C, Traintinger S, Nienaber U, Tacacs-Tolnai A, Windhofer C, Bahrami S, Voelckel W: Thromboelastometric (ROTEM) findings in patients suffering from isolated severe traumatic brain injury. *J Neurotrauma* 2011; 28: 2033-41.
- 13) Goodnight SH, Kenoyer G, Rapaport SI, Patch MJ, Lee JA, Kurze T: Defibrination after brain-tissue destruction: A serious complication of head injury. *N Engl J Med* 1974; 290: 1043-7.
- 14) Kushimoto S, Shibata Y, Yamamoto Y: Implications of fibrinogenolysis in patients with closed head injury. *J Neurotrauma* 2003; 20: 357-63.
- 15) Hiippala ST, Myllyla GJ, Vahtera EM: Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. *Anesth Analg* 1995; 81: 360-5.
- 16) Hiippala S: Replacement of massive blood loss. *Vox Sang* 1998; 74 Suppl 2: 399-407.
- 17) McLoughlin TM, Fontana JL, Alving B, Mongan PD, Bunger R: Profound normovolemic hemodilution: hemostatic effects in patients and in a porcine model. *Anesth Analg* 1996; 83: 459-65.

- 18) White NJ, Martin EJ, Brophy DF, Ward KR: Coagulopathy and traumatic shock: characterizing hemostatic function during the critical period prior to fluid resuscitation. *Resuscitation*. 2010; 81: 111-6.
- 19) Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Stahel PF, Vincent JL, Spahn DR, Task Force for Advanced Bleeding Care in Trauma: Management of bleeding following major trauma: an updated European guideline. *Crit Care*. 2010; 14: R52.
- 20) Bolliger D, Gorlinger K, Tanaka KA: Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. *Anesthesiology* 2010; 113: 1205-19.
- 21) Ozier Y, Hunt BJ: Against: Fibrinogen concentrate for management of bleeding: against indiscriminate use. *J Thromb Haemost* 2011; 9: 6-8.
- 22) Lier H, Bottiger BW, Hinkelbein J, Krep H, Bernhard M: Coagulation management in multiple trauma: a systematic review. *Intensive Care Med* 2011; 37: 572-82.
- 23) Spahn DR, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Filipescu D, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Vincent JL, Rossaint R: Management of bleeding and

coagulopathy following major trauma: an updated European guideline. *Crit Care* 2013; 17: R76.

24) Spahn DR, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, Gordini G, Stahel PF, Hunt BJ, Komadina R, Neugebauer E, Ozier Y, Riddez L, Schultz A, Vincent JL, Rossaint R; Task Force for Advanced Bleeding Care in Trauma: Management of bleeding following major trauma: a European guideline. *Crit Care*. 2007; 11: R17.

25) O'Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, Williamson LM; British Committee for Standards in Haematology, Blood Transfusion Task Force: Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. *Br J Haematol* 2004; 126: 11-28.

26) British Committee for Standards in Haematology, Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton PJ: Guidelines on the management of massive blood loss. *Br J Haematol* 2006; 135: 634-41.

27) Gaarder C, Naess PA, Frischknecht Christensen E, Hakala P, Handolin L, Heier HE, Ivancev K, Johansson P, Leppäniemi A, Lippert F, Lossius HM, Opdahl H, Pillgram-Larsen J, Røise O, Skaga NO, Søreide E, Stensballe J, Tønnessen E, Töttermann A, Ortenwall P, Ostlund A: Scandinavian Guidelines--"The massively bleeding patient". *Scand J Surg* 2008; 97: 15-36.

- 28) Stinger HK, Spinella PC, Perkins JG, Grathwohl KW, Salinas J, Martini WZ, Hess JR, Dubick MA, Simon CD, Beekley AC, Wolf SE, Wade CE, Holcomb JB: The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. *J Trauma* 2008; 64: S79-85; discussion S85.
- 29) Wafaisade A, Lefering R, Maegele M, Brockamp T, Mutschler M, Lendemans S, Banerjee M, Bouillon B, Probst C; Trauma Registry of DGU: Administration of fibrinogen concentrate in exsanguinating trauma patients is associated with improved survival at 6 hours but not at discharge. *J Trauma Acute Care Surg* 2013; 74: 387-3; discussion 393-5.
- 30) Ranucci M, Solomon C: Supplementation of fibrinogen in acquired bleeding disorders: experience, evidence, guidelines, and licences. *Br J Anaesth* 2012; 109: 135-7.
- 31) Nienaber U, Innerhofer P, Westermann I, Schochl H, Attal R, Breitkopf R, Maegele M: The impact of fresh frozen plasma vs coagulation factor concentrates on morbidity and mortality in trauma-associated haemorrhage and massive transfusion. *Injury* 2011; 42: 697-701.

- 32) Dickneite G, Pragst I, Joch C, Bergman GE: Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P). *Blood Coagul Fibrinolysis* 2009; 20: 535-40.
- 33) Meyer MA, Ostrowski SR, Windeløv NA, Johansson PI: Fibrinogen concentrates for bleeding trauma patients: what is the evidence? *Vox Sang* 2011; 101: 185-90.
- 34) Copes WS, Champion HR, Sacco WJ, Lawnick MM, Keast SL, Bain LW: The Injury Severity Score revisited. *J Trauma* 1988; 28: 69-77.
- 35) Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Murata A, Ikeda T, Ishikura H, Ueyama M, Ogura H, Kushimoto S, Saitoh D, Endo S, Shimazaki S; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group: A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. *Crit Care Med* 2006; 34: 625-31.
- 36) Holcomb JB, Fox EE, Zhang X, White N, Wade CE, Cotton BA, del Junco DJ, Bulger EM, Cohen MJ, Schreiber MA, Myers JG, Brasel KJ, Phelan HA, Alarcon LH, Muskat P, Rahbar MH: Cryoprecipitate use in the PROMMTT study. *J Trauma Acute Care Surg* 2013; 75: S31-9.

37) Hoyt DB, Dutton RP, Hauser CJ, Hess JR, Holcomb JB, Kluger Y,

Mackway-Jones K, Parr MJ, Rizoli SB, Yukioka T, Bouillon B: Management of coagulopathy in the patients with multiple injuries: results from an international survey of clinical practice. *J Trauma* 2008; 65: 755-64; discussion 764-5.

## Figure legends

### Figure 1

#### **Kaplan–Meier estimation curves for all patients**

The curves show the time from arrival at the emergency department to reaching the critical levels of routine coagulation parameters as well as meeting the criteria for massive transfusion. The critical levels of the routine coagulation parameters were as follows: platelet count,  $\leq 50$  or  $\leq 100 \times 10^9/L$ ; prothrombin time-internal normalized ratio (PT-INR),  $\geq 1.5$ ; activated partial thromboplastin time (APTT),  $\geq 60$  s; fibrinogen level,  $\leq 1.5$  g/L. Massive transfusion was defined as  $>10$  units red cell concentrates.

### Figure 2

#### **Kaplan–Meier estimation curves in patients with and without DIC**

Figure 1





Figure 2



## Tables

Table 1 Patient characteristics

	All patients			<i>P</i> value
	<i>n</i> = 80	DIC <i>n</i> = 35	Non-DIC <i>n</i> = 45	
Male	57 (71.3)	24 (68.6)	33 (73.3)	0.641
Age, years	50 (33–67)	43 (29–68)	52 (41–66)	0.225
Anticoagulant/antiplatelet use	3 (3.8)	1 (2.9)	2 (4.4)	0.711
Cirrhosis	2 (2.5)	2 (5.7)	0 (0.0)	0.104
Fluid administration before arrival	20 (25)	7 (20)	13 (29)	0.440
Fluid amounts before arrival, mL	0 (0–38)	0 (0–0)	0 (0–75)	0.467
Time from accident to arrival at ED				

0–30 minutes	33 (41.3)	16 (45.7)	17 (3.78)	
31–60 minutes	35 (43.8)	14 (40.0)	21 (46.7)	
>61 minutes	10 (12.5)	3 (8.6)	7 (15.6)	0.279
Unknown	2 (2.5)	2 (5.7)	0 (0.0)	
SIRS score	2 (1–3)	3 (2–3)	2 (1–29)	< 0.001
DIC score	3 (3–4)	4 (4–5)	3 (1–3)	< 0.001
Blunt injury	79 (98.8)	35 (100.0)	44 (97.8)	0.375
ISS	26 (20–34)	30 (20–36)	24 (20–29)	0.047
Head/neck AIS $\geq 3$	55 (68.7)	27 (77.1)	28 (62.2)	0.153
Face AIS $\geq 3$	3 (3.8)	1 (2.9)	2 (4.4)	0.711
Chest AIS $\geq 3$	41 (51.3)	16 (45.7)	25 (55.6)	0.382
Abdomen AIS $\geq 3$	13 (16.3)	10 (28.6)	3 (6.7)	0.008

Extremity AIS $\geq 3$	25 (31.3)	15 (42.9)	10 (22.2)	0.048
External AIS $\geq 3$	1 (1.3)	1 (2.9)	0 (0.0)	0.254
Glasgow coma scale	12 (6–14)	8 (4–13)	13 (8–14)	0.025
Systolic blood pressure, mmHg	120 (90–140)	106 (83–106)	132 (95–105)	0.011
Heart rate, beats/min	82 (70–105)	100 (72–121)	80 (69–85)	0.003
Respiratory rate, breaths/min	24 (18–28)	24 (19–29)	24 (18–26)	0.322
Body temperature, °C	36.0 (35.5–36.7)	36.0 (35.2–37.2)	36.1 (35.5–36.6)	0.703
Revised trauma score	6.90 (4.79–7.84)	5.97 (4.09–7.84)	7.11 (5.97–7.84)	0.024

---

All measurements are expressed as the median (IQR) or number (%).

ED, emergency department; SIRS, systemic inflammatory response syndrome; DIC, disseminated intravascular coagulation; ISS, injury severity score; AIS, abbreviated injury score.

Table 2 Laboratory results on arrival at the emergency department

	All patients			<i>P</i> value
	<i>n</i> = 80	DIC <i>n</i> = 35	Non-DIC <i>n</i> = 45	
Laboratory tests				
White blood cell ( $\times 10^9$ cells/L)	12.6 (9.0–16.4)	15.8 (10.4–17.7)	10.9 (8.8–14.7)	0.010
Hemoglobin (g/dL)	12.8 (11.1–14.6)	12.2 (9.9–14.1)	13.1 (11.8–14.9)	0.033
Platelet count ( $\times 10^9$ cells/L)	201 (151–236)	198 (135–221)	202 (159–248)	0.252
Aspartate aminotransferase (U/L)	50 (35–118)	101 (42–215)	42 (32–86)	0.002
Alanine aminotransferase (U/L)	42 (29–73)	68 (38–164)	33 (26–47)	0.012
Lactate dehydrogenase (U/L)	431 (321–597)	521 (375–751)	365 (283–489)	0.004
Creatine kinase (U/L)	273 (176–517)	290 (211–654)	254 (167–420)	0.118

Prothrombin time (s)	12.2 (11.4–14.0)	13.7 (12.1–15.0)	11.6 (11.1–12.7)	<0.001
PT-INR	1.06 (0.98–1.17)	1.15 (1.06–1.30)	1.00 (0.97–1.09)	<0.001
Activated partial thromboplastin time (s)	31.5 (28.5–38.0)	36.2 (31.6–47.2)	29.6 (27.1–31.9)	<0.001
Fibrinogen (g/L)	1.81 (1.42–2.07)	1.59 (1.13–1.83)	1.96 (1.73–2.37)	<0.001
Fibrin/fibrinogen degradation products (µg/mL)	73.9 (28.8–123.3)	99.5 (49.2–211)	46.0 (13.7–89.7)	<0.001
D-dimer (µg/mL)	50.3 (19.7–83.3)	69.1 (37.4–124.8)	35.4 (11.1–64.5)	<0.001
FDP/D-dimer ratio	1.39 (1.29–1.56)	1.50 (1.31–1.72)	1.33 (1.27–1.48)	0.008
Antithrombin (%)	86 (71–95)	74 (65–92)	89 (79–97)	0.010

Patients with critical hemostatic abnormality on arrival

PT-INR $\geq$ 1.5	2 (2.5)	2 (5.7)	0	0.188
APTT $\geq$ 60 s	3 (3.8)	2 (5.7)	1 (2.2)	0.578
Platelet count $\leq$ $50 \times 10^9$ cells/L	0	0	0	-

Platelet count $\leq 100 \times 10^9$ cells/L	2 (2.5)	2 (5.7)	0	0.188
Fibrinogen $\leq 1.5$ g/L	22 (27.5)	17 (48.6)	5 (11.1)	<0.001

---

All measurements are expressed as the median (IQR) or number (%).

DIC, disseminated intravascular coagulation; PT-INR, prothrombin time-international normalized ratio; FDP, fibrin degradation product; APTT, activated partial thromboplastin time.

Table 3 Transfusions during the first 6 and 24 hours

	All patients			<i>P</i> value
	<i>n</i> = 80	DIC <i>n</i> = 35	Non-DIC <i>n</i> = 45	
Transfusions during the first 6 hours				
RCC transfusion	30 (37.5)	19 (54.3)	11 (24.4)	0.010
RCC, unit	0 (0–6)	4 (0–25)	0 (0–1)	0.002
Massive transfusion	18 (22.5)	13 (31.1)	5 (11.1)	0.007
FFP transfusion	31 (38.8)	20 (57.1)	11 (24.4)	0.005
FFP, unit	0 (0–8)	4 (0–34)	0 (0–2)	0.001
Platelet concentrate transfusion	12 (15.0)	12 (34.4)	0 (0.0)	<0.001
Platelet, unit	0 (0–0)	0 (0–20)	0	<0.001

Fibrinogen concentrate administration	26 (32.5)	19 (54.3)	7 (15.6)	<0.001
Fibrinogen concentrate, g	0 (0–3)	3 (0–3)	0 (0–0)	<0.001
Total fibrinogen administration, g	0.0 (0.0–6.4)	5.4 (0–22.6)	0.0 (0.0–1.6)	0.001
Transfusions during the first 24 hours				
RCC transfusion	32 (40.0)	20 (57.1)	12 (26.7)	0.006
RCC, unit	0 (0–10)	12 (3–45)	0 (0–4)	0.001
Massive transfusion	22 (27.5)	15 (42.9)	7 (15.6)	0.007
FFP transfusion, <i>n</i>	30 (37.5)	21 (60.0)	9 (20.0)	<0.001
FFP, unit	0 (0–13)	18 (5–63)	0 (0–0)	<0.001
Platelet concentrate transfusion	15 (18.8)	13 (37.1)	2 (4.4)	<0.001
Platelet, unit	0 (0–0)	0 (10–20)	0 (0–0)	<0.001

Fibrinogen concentrate administration	30 (37.5)	20 (57.1)	10 (22.2)	0.001
Fibrinogen concentrate, g	0 (0–3)	3 (3–6)	0 (0–3)	0.001
Total fibrinogen administration, g	0.0 (0.0–7.7)	6.2 (0.0–28.2)	0.0 (0.0–3.0)	<0.001

---

All measurements are expressed as the median (IQR) or number (%). Total fibrinogen administration was calculated according to standard amounts of fibrinogen contained in each blood components (1 unit FFP: 400 mg fibrinogen; 1 unit platelet concentrate: 300 mg fibrinogen).

DIC, disseminated intravascular coagulation; RCC, red cell concentrate; FFP, fresh frozen plasma.

Table 4 Treatments and outcomes

	All patients			<i>P</i> value
	<i>n</i> = 80	DIC <i>n</i> = 35	Non-DIC <i>n</i> = 45	
Emergency operation for hemostasis	9 (11.3)	7 (20.0)	2 (4.4)	0.029
Interventional radiology for hemostasis	7 (8.8)	5 (14.3)	2 (4.4)	0.122
Other emergency operation	21 (26.3)	9 (25.7)	12 (26.7)	0.923
Tranexamic acid administration during the first 3 hours	30 (37.5)	15 (42.9)	15 (33.3)	0.383
Outcome				
Death within 24 hours	2 (2.5)	2 (5.7)	0 (0.0)	0.104
Death within 48 hours	2 (2.5)	2 (5.7)	0 (0.0)	0.104
In-hospital death	9 (11.3)	6 (17.1)	3 (6.7)	0.141

---

All measurements are expressed as number (%).

DIC, disseminated intravascular coagulation

Table 5 Associations among routine coagulation parameters in Kaplan–Meier curves

<i>P</i> value (Log-rank test)	PT-INR ≥1.5	APTT ≥60 s	Platelet count ≤50 × 10 <sup>9</sup> /L	Platelet count ≤100 × 10 <sup>9</sup> /L	Fibrinogen ≤1.5 g/L	Massive transfusion
PT-INR ≥ 1.5	—	0.831	0.349	<0.001	<0.001	0.005
APTT ≥ 60 s	0.831	—	0.260	<0.001	<0.001	0.007
Platelet count ≤ 50 × 10 <sup>9</sup> cells/L	0.349	0.260	—	0.001	<0.001	0.095
Platelet count ≤ 100 × 10 <sup>9</sup> cells/L	<0.001	<0.001	0.001	—	0.023	0.121
Fibrinogen ≤1.5 g/L	<0.001	<0.001	<0.001	0.023	—	<0.001
Massive transfusion	0.005	0.007	0.095	0.121	<0.001	—

*P* values are the results of the log-rank tests between each curve in Kaplan–Meier analysis in Figure 1.

PT-INR, prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time